118 related articles for article (PubMed ID: 15302989)
1. Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model.
Takai S; Jin D; Sakaguchi M; Muramatsu M; Ishii K; Kirimura K; Sakonjo H; Miyazaki M
Hypertens Res; 2004 Jul; 27(7):517-22. PubMed ID: 15302989
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Kim S; Zhan Y; Izumi Y; Iwao H
Hypertension; 2000 Mar; 35(3):769-74. PubMed ID: 10720593
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet.
Takai S; Kim S; Sakonjo H; Miyazaki M
J Hypertens; 2003 Feb; 21(2):361-9. PubMed ID: 12569267
[TBL] [Abstract][Full Text] [Related]
5. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet.
Miyazaki M; Sakonjo H; Takai S
Br J Pharmacol; 1999 Oct; 128(3):523-9. PubMed ID: 10516628
[TBL] [Abstract][Full Text] [Related]
6. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys.
Song K; Shiota N; Takai S; Takashima H; Iwasaki H; Kim S; Miyazaki M
Atherosclerosis; 1998 May; 138(1):171-82. PubMed ID: 9678783
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats.
Yao K; Sato H; Ina Y; Suzuki K; Ohno T; Shirakura S
Hypertens Res; 2003 Aug; 26(8):635-41. PubMed ID: 14567503
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model.
Johnstone MT; Perez AS; Nasser I; Stewart R; Vaidya A; Al Ammary F; Schmidt B; Horowitz G; Dolgoff J; Hamilton J; Quist WC
Circulation; 2004 Oct; 110(14):2060-5. PubMed ID: 15451796
[TBL] [Abstract][Full Text] [Related]
10. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
11. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats.
Kim-Mitsuyama S; Yamamoto E; Tanaka T; Zhan Y; Izumi Y; Izumiya Y; Ioroi T; Wanibuchi H; Iwao H
Stroke; 2005 May; 36(5):1083-8. PubMed ID: 15817892
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
13. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
14. MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality.
Pernomian L; do Prado AF; Gomes MS; Pernomian L; da Silva CHTP; Gerlach RF; de Oliveira AM
Eur J Pharmacol; 2015 Oct; 764():173-188. PubMed ID: 26144375
[TBL] [Abstract][Full Text] [Related]
15. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Minatoguchi S; Aoyama T; Kawai N; Iwasa M; Oda M; Kida K; Kojima S; Goto N; Goto M; Sugishita F; Takai K; Tanaka R; Hiei K; Minagawa T; Yamamoto N; Watanabe I; Yasue T; Kobayashi H
Blood Press; 2013 Sep; 22 Suppl 1():29-37. PubMed ID: 23330658
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.
Doran DE; Weiss D; Zhang Y; Griendling KK; Taylor WR
Atherosclerosis; 2007 Nov; 195(1):39-47. PubMed ID: 17224157
[TBL] [Abstract][Full Text] [Related]
17. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet.
Takai S; Jin D; Sakaguchi M; Muramatsu M; Miyazaki M
J Hypertens; 2005 Oct; 23(10):1879-86. PubMed ID: 16148612
[TBL] [Abstract][Full Text] [Related]
18. Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Skoczylas A; Piecha G; Więcek A
Pol Arch Med Wewn; 2016 Apr; 126(4):243-53. PubMed ID: 27129086
[TBL] [Abstract][Full Text] [Related]
19. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
Takahara A; Nakamura Y; Wagatsuma H; Aritomi S; Nakayama A; Satoh Y; Akie Y; Sugiyama A
Br J Pharmacol; 2009 Nov; 158(5):1366-74. PubMed ID: 19785655
[TBL] [Abstract][Full Text] [Related]
20. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Sueta D; Nakamura T; Dong YF; Kataoka K; Koibuchi N; Yamamoto E; Toyama K; Yasuda O; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2012 Jun; 25(6):704-10. PubMed ID: 22421905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
